Jiuzhitang Co.,Ltd.(000989.SZ): A new drug developed by its controlled subsidiary has initiated Phase IIb clinical trials.
Jiuzhitang Co., Ltd. (000989.SZ) announced that on November 13, 2026, its controlled subsidiary Jiuzhitang Meike (Beijing) Cell Technology Co., Ltd. ("Beijing Meike") and the lead clinical trial site, the First Affiliated Hospital of Guangzhou Medical University, convened the kick-off meeting for "a multicenter, randomized, double-blind, placebo-controlled Phase IIb clinical trial evaluating the efficacy and safety of human bone marrow mesenchymal stem cell (hBMMSC) injection in the treatment of autoimmune pulmonary alveolar proteinosis (aPAP)."
Jiuzhitang Co.,Ltd. (000989.SZ) announced that on November 13, 2026, its controlled subsidiary Jiuzhitang Meike (Beijing) Cell Technology Co., Ltd. ("Beijing Meike") and the lead clinical trial site, the First Affiliated Hospital of Guangzhou Medical University, organized the kick-off meeting for "a multicenter, randomized, double-blind, placebo-controlled Phase IIb clinical trial evaluating the efficacy and safety of human bone marrow mesenchymal stem cell (hBMMSC) injection in the treatment of autoimmune pulmonary alveolar proteinosis (aPAP)."
The investigational drug for this clinical trial is human bone marrow mesenchymal stem cell (hBMMSC) injection, which is registered as a Class 1 new drug and falls under the regulatory classification of therapeutic biological products. The proposed indication for this drug is autoimmune pulmonary alveolar proteinosis (aPAP). The stem cell product used in this clinical trial is human bone marrow mesenchymal stem cell (hBMMSC) injection, independently developed and produced by Beijing Meike.
Related Articles
.png)
AI cloud provider Nscale's debt surges ahead of listing, deepening reliance on NVIDIA Corporation (NVDA.US) for funding and chip supply
US Stock Market Move | NVIDIA Corporation (NVDA.US) opened higher but closed lower, falling more than 4%; a well-known investment bank says there is still considerable uncertainty surrounding management changes.
Strong AI computing demand cannot mask data center delivery delay risks; Morgan Stanley maintains Nebius (NBIS.US) "Equal-weight" rating and US$144 price target.
AI cloud provider Nscale's debt surges ahead of listing, deepening reliance on NVIDIA Corporation (NVDA.US) for funding and chip supply
US Stock Market Move | NVIDIA Corporation (NVDA.US) opened higher but closed lower, falling more than 4%; a well-known investment bank says there is still considerable uncertainty surrounding management changes.
Strong AI computing demand cannot mask data center delivery delay risks; Morgan Stanley maintains Nebius (NBIS.US) "Equal-weight" rating and US$144 price target.
